DiNuzzo Private Wealth Inc. Takes Position in Eli Lilly and Company (NYSE:LLY)

DiNuzzo Private Wealth Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, HoldingsChannel reports. The firm bought 119 shares of the company’s stock, valued at approximately $69,000.

Several other hedge funds have also recently bought and sold shares of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the third quarter worth about $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Finally, The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $742.95.

Eli Lilly and Company Stock Performance

LLY stock traded down $0.66 during midday trading on Wednesday, reaching $780.44. 1,704,690 shares of the company were exchanged, compared to its average volume of 3,054,071. Eli Lilly and Company has a one year low of $399.26 and a one year high of $800.78. The firm has a market capitalization of $741.54 billion, a price-to-earnings ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The business has a 50-day moving average price of $761.41 and a two-hundred day moving average price of $669.21. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the company posted $1.62 EPS. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.